A pharmacogenetic analysis using a genome‐wide approach in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial identified HSD17B3, SMAD3, and IPO11 as genetic markers of fenofibrate response.17 Here, HSD17B3 is linked to diabetes mellitus.